- Home
- HNRG vs TRVI Comparison
HNRG vs TRVI Comparison
Compare HNRG & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- TRVI
- Stock Information
- Founded
- HNRG 1949
- TRVI 2011
- Country
- HNRG United States
- TRVI United States
- Employees
- HNRG N/A
- TRVI N/A
- Industry
- HNRG Coal Mining
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- TRVI Health Care
- Exchange
- HNRG Nasdaq
- TRVI Nasdaq
- Market Cap
- HNRG 413.8M
- TRVI 383.4M
- IPO Year
- HNRG N/A
- TRVI 2019
- Fundamental
- Price
- HNRG $12.51
- TRVI $6.50
- Analyst Decision
- HNRG Strong Buy
- TRVI Strong Buy
- Analyst Count
- HNRG 2
- TRVI 8
- Target Price
- HNRG $15.00
- TRVI $17.56
- AVG Volume (30 Days)
- HNRG 743.4K
- TRVI 4.4M
- Earning Date
- HNRG 03-17-2025
- TRVI 03-18-2025
- Dividend Yield
- HNRG N/A
- TRVI N/A
- EPS Growth
- HNRG N/A
- TRVI N/A
- EPS
- HNRG N/A
- TRVI N/A
- Revenue
- HNRG $404,394,000.00
- TRVI N/A
- Revenue This Year
- HNRG N/A
- TRVI N/A
- Revenue Next Year
- HNRG $19.94
- TRVI N/A
- P/E Ratio
- HNRG N/A
- TRVI N/A
- Revenue Growth
- HNRG N/A
- TRVI N/A
- 52 Week Low
- HNRG $4.33
- TRVI $2.30
- 52 Week High
- HNRG $14.00
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- HNRG 61.38
- TRVI 66.37
- Support Level
- HNRG $12.12
- TRVI $6.22
- Resistance Level
- HNRG $12.98
- TRVI $6.79
- Average True Range (ATR)
- HNRG 0.86
- TRVI 0.40
- MACD
- HNRG 0.24
- TRVI -0.03
- Stochastic Oscillator
- HNRG 80.97
- TRVI 52.24
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.